Objective: To investigate the efficacy of Aidi injection combined with doctaxel combined with cisplatin(DP) chemotherapy regimen in female patients with advanced non-small cell lung cancer (NSCLC)

and observe its effect on cellular immune function and quality of life. Method: We retrospectively analyzed clinical data of seventy-nine patients with advanced NSCLC. According to treatment regimens

they were divided into treatment group (41 cases) and control group (38 cases). Patients in control group were treated with DP regimen only

while patients in treatment group were treated with Aidi injection combined with DP chemotherapy regimen. Treatment for 21 days was regarded as one cycle

and evaluation was conducted after two cycles. Result: Efficacy was 51.2% in treatment group and 39.5% in control group. Disease control rate was 82.1% in treatment group and 66.7% in control group

with statistically significant difference between two groups (P<0.05). In treatment group

counts of CD3+ T cells

CD4+ T cells and CD4+/CD8+ after treatment were significantly higher than those before treatment and those in control group

while the count of CD8+ T cells was decreased (P<0.05

P<0.01). In treatment group

scores of domains in physiological status

social and family status and total scores after treatment were improved than those before treatment and those in control group (P<0.05

P<0.01). Major adverse effects included bone marrow suppression and gastrointestinal reactions. Incidences of leukopenia of Ⅲ/Ⅳ degree and decreased hemoglobin in treatment group were lower than those in control group

with statistically significant difference between two groups. Conclusion: Aidi injection combined with DP regimen could improve the efficacy

cellular immune function and quality of life in female patients with advanced NSCLC. Furthermore

it could decrease toxic and adverse effects

so it is worthy of further clinical application and promotion.